Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Money and medicine collide at end of life. A large Medicare study found that patients treated by oncologists who received industry payments were more likely to receive aggressive end-of-life care — including more chemo, fewer hospice referrals, and more ER visits. The findings are reigniting calls for greater financial transparency between physicians and their patients.
A new Medicare study is raising important questions about how financial ties between oncologists and drug manufacturers may shape care decisions in a patient's final days. Researchers found that patients whose oncologists received industry payments were modestly but meaningfully more likely to receive aggressive end-of-life care — including more chemotherapy, more hospitalizations, and less hospice time.
The study, presented at the 2026 ASCO Quality Care Symposium, analyzed over 52,000 Medicare patients with lung, breast, colorectal, pancreatic, or prostate cancer. Notably, nearly three-quarters of patients had an oncologist who received relevant industry payments — and the effect appeared to be all-or-none, with no dose-response based on payment size.
By the Numbers:
Why it matters: This observational study cannot prove causation, but it adds to a growing debate about financial conflicts in oncology. Experts are calling for stronger disclosure requirements — so patients know whether their doctor has financial incentives that could influence their care, especially at life's most vulnerable moments.
